Retrospective data has shown that some pre-formed and de novo Donor-Specific Alloantibodies (DSA) impair patient and graft survival of liver transplant and simultaneous liver-kidney transplantation (SLKT) patients (1-14). However, not all patients with DSA in their serum have impaired outcomes. Although no consensus exists regarding all the different pathologic outcomes of DSA, acute antibody mediated rejection is known to occur more commonly in patients with preformed persistent DSA and is currently being defined by the Banff group (11, 12, 15-18). In addition, chronic AMR is also seen, but criteria for diagnosis are currently lacking (9, 19). Currently there are no definitive ways to determine the patient, donor, and antibody characteristics that are associated with acute and chronic problems related to alloimmunity in recipients of LT and SLKT. Therefore, it is imperative to perform a prospective clinical trial to evaluate the patient, donor, and antibody characteristics associated with a variety of poor outcomes. To achieve this goal, we created a multicenter group that will study donor specific alloantibodies in liver transplantation and SLKT to correlate patient, donor and antibody characteristics with outcomes.
|Effective start/end date||5/5/17 → 5/4/18|
- Baylor Research Institute (AGREEMENT 5/12/17)